Recent publications
Article
Razak, RA, Fletcher, P, Kunene, V & Ma, YT 2021, 'Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma', Journal of Clinical Gastroenterology, vol. 55, no. 2, pp. 169-173. https://doi.org/10.1097/MCG.0000000000001375
Virtakoivu, R, Rannikko, JH, Viitala, M, Vaura, F, Takeda, A, Lönnberg, T, Koivunen, J, Jaakkola, P, Pasanen, A, Shetty, S, Jonge, MJAD, Robbrecht, D, Ma, YT, Skyttä, T, Minchom, A, Jalkanen, S, Karvonen, MK, Mandelin, J, Bono, P & Hollmen, M 2021, 'Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: results from a phase I/II clinical trial', Clinical Cancer Research, vol. 27, no. 15, pp. 4205-4220. https://doi.org/10.1158/1078-0432.CCR-20-4862
Sagar, VM, Herring, K, Curbishley, S, Hodson, J, Fletcher, P, Karkhanis, S, Mehrzad, H, Punia, P, Shah, T, Shetty, S & Ma, YT 2021, 'The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study', OncoTarget, vol. 12, no. 24, pp. 2338-2350. https://doi.org/10.18632/oncotarget.28136
Johnson, PJ, Dhanaraj, S, Berhane, S, Bonnett, L & Ma, YT 2021, 'The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study', British Journal of Cancer, vol. 125, no. 5, pp. 714-716. https://doi.org/10.1038/s41416-021-01445-3
Ma, YT 2020, 'MTL-CEBPA, a Small Activating RNA Therapeutic Up-Regulating C/EBP-α, in Patients With Advanced Liver Cancer: A First-In-Human, Multi-Centre, Open-Label, Phase I Trial', Clinical Cancer Research.
Kalisvaart, M, Broadhurst, D, Marcon, F, Pande, R, Schlegel, A, Sutcliffe, R, Marudanayagam, R, Mirza, D, Chatzizacharias, N, Abradelo, M, Muiesan, P, Isaac, J, Ma, YT, Mcconville, C & Roberts, K 2020, 'Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study', HPB : the official journal of the International Hepato Pancreato Biliary Association, vol. 22, no. 9, pp. 1240-1249. https://doi.org/10.1016/j.hpb.2020.01.005
Corrie, PG, Qian, W, Basu, B, Valle, JW, Falk, S, Lwuji, C, Wasan, H, Palmer, D, Scott-brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, Mcadam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, YT, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, DI 2020, 'Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma', British Journal of Cancer, vol. 122, no. 12, pp. 1760–1768. https://doi.org/10.1038/s41416-020-0846-2
Palmer, DH, Valle, JW, Ting Ma, Y, Faluyi, O, Neoptolemos, JP, Jensen Gjertsen, T, Iversen, B, Amund Eriksen, J, Møller, A, Aksnes, A, Miller, R & Dueland, S 2020, 'TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial', British Journal of Cancer, vol. 122, no. 7, pp. 971–977. https://doi.org/10.1038/s41416-020-0752-7
Ma, YT 2020, 'Treatment strategies for the optimal management of locally advanced pancreatic adenocarcinoma with curative intent: A systematic review.', Pancreas.
BILCAP study group, Primrose, JN, Fox, RP, Palmer, DH, Malik, HZ, Prasad, R, Mirza, D, Anthony, A, Corrie, P, Falk, S, Finch-Jones, M, Wasan, H, Ross, P, Wall, L, Wadsley, J, Evans, JTR, Stocken, D, Praseedom, R, Ma, YT, Davidson, B, Neoptolemos, JP, Iveson, T, Raftery, J, Zhu, S, Cunningham, D, Garden, OJ, Stubbs, C, Valle, JW & Bridgewater, J 2019, 'Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study', The Lancet Oncology, vol. 20, no. 5, pp. 663-673. https://doi.org/10.1016/S1470-2045(18)30915-X
Dasari, BVM & Ma, YT 2019, 'Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver', HPB : the official journal of the International Hepato Pancreato Biliary Association. https://doi.org/10.1016/j.hpb.2019.07.007
Ahsan Javed, M & Ma, YT 2019, 'Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.', Pancreatology, vol. 19, no. 1, pp. 97-104. https://doi.org/10.1016/j.pan.2018.10.003
Ma, YT 2019, 'Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial', JAMA Surgery.
Palmer, DH, Ma, Y, Peck-Radosavljevic, M, Ross, P, Graham, J, Fartoux, L, Deptala, A, Studeny, M, Schnell, D, Hocke, J, Loembe, A-B & Meyer, T 2018, 'A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of Nintedanib vs. Sorafenib in European patients with advanced hepatocellular carcinoma', British Journal of Cancer, vol. 118, pp. 1162-1168. https://doi.org/10.1038/s41416-018-0051-8
Afshar, M, Fletcher, P, Bardoli, A, Ma, Y & Punia, P 2018, 'Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort', OncoTarget, vol. 9, no. 24, pp. 16988–16995. https://doi.org/10.18632/oncotarget.24769
View all publications in research portal